Celgene opens door for early launch of Revlimid generics

Emily Wasserman

Just in time for the holidays, settled the score with Natco Pharma over patents for its cancer blockbuster . The company is allowing the Indian maker to start selling copycat versions of its best-selling drug before goes completely off patent in 2027, but with a few strings attached.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS